Biomed Industries to Present Phase 2 Data on NA-931—an Oral Alternative to Injectables for Obesity—at ObesityWeek® 2025
Biomed Industries, Inc. to Present Breakthrough Phase 2 Data on NA-931—an Oral Alternative to Injectables for Obesity—at ObesityWeek® 2025 SAN JOSE, CA, UNITED STATES, October 30, 2025 /EINPresswire.com/ -- — Biomed Industries, Inc. (“Biomed”) …